01 1Hovione FarmaCiencia SA
01 1Paltusotine.HCl SDD
01 1Portugal
NDC Package Code : 50909-1913
Start Marketing Date : 2025-09-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (15kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
23
PharmaCompass offers a list of Paltusotine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Paltusotine manufacturer or Paltusotine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Paltusotine manufacturer or Paltusotine supplier.
PharmaCompass also assists you with knowing the Paltusotine API Price utilized in the formulation of products. Paltusotine API Price is not always fixed or binding as the Paltusotine Price is obtained through a variety of data sources. The Paltusotine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Paltusotine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Paltusotine, including repackagers and relabelers. The FDA regulates Paltusotine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Paltusotine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Paltusotine supplier is an individual or a company that provides Paltusotine active pharmaceutical ingredient (API) or Paltusotine finished formulations upon request. The Paltusotine suppliers may include Paltusotine API manufacturers, exporters, distributors and traders.
click here to find a list of Paltusotine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Paltusotine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Paltusotine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Paltusotine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Paltusotine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Paltusotine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Paltusotine suppliers with NDC on PharmaCompass.
